Hematologic abnormalities are often seen in patients infected with human immunodeficiency virus (HIV). The effect of HIV infection of bone marrow stroma on support of uninfected CD34 progenitor cells in long-term bone marrow culture (LTBMC) was investigated. Results show that HIV-infected bone marrow stroma was unable to adequately support CD34 progenitor cells in vitro. Zidovudine or didanosine was added to cultures in an attempt to reverse the suppressive effects exerted by HIV and to determine whether such suppression was mediated by transfer of HIV infection to progenitor cells. Didanosine failed to reduce the suppressive effects of HIV, whereas zidovudine compounded the observed suppression. HIV infection of bone marrow stroma, while reducing the production of nonadherent cells, did not increase apoptosis and cell death in such cells. In contrast, zidovudine enhanced apoptosis and cell death in nonadherent cells produced by both HIV-infected and control LTBMC.
Hematologic disorders, such as anemia, thrombocytopenia, cells, with some workers reporting inability to infect progenitor cells in vitro [15, 16] and others demonstrating infection of and other cytopenias, are common in patients infected with human immunodeficiency virus (HIV) and are most frequent differentiated progenitor cells [17, 18] . Infection of progenitor cells has been reported in vivo, but only in a subset of seroposiin patients with advanced stages of disease [1, 2] . Several mechanisms have been proposed to account for cytopenias, tive persons [19] . It is therefore unclear whether suppression of bone marrow function is due to direct effects of HIV infecincluding direct infection of bone marrow progenitor cells [3] and impairment of stromal function [4 -9] . In addition, drug tion of bone marrow stromal macrophages or whether it is a result of transfer of HIV from infected stroma to circulating therapies used in the treatment of HIV and opportunistic infections may lead to bone marrow suppression.
progenitors. Bone marrow macrophages are pivotal in support of hemopoiesis by bone marrow stroma; thus, modulation of Bone marrow consists of two closely interacting groups of cells: stromal cells (fibroblasts, adipocytes, endothelial cells, their function by HIV infection is highly likely to affect hemopoiesis. Furthermore, release of HIV proteins from such cells and macrophages) and hemopoietic cells (progenitor and mature cell types) [10, 11] . Growth and differentiation of hemo-(gp120, Tat, Nef) may have direct cytotoxic effects on progenitor cells, leading to apoptosis and cell death [4 -6] . poietic cells are dependent on their close association with stromal cells, which produce regulatory cytokines necessary to This study investigated the effect of HIV infection of bone marrow stroma on its ability to support uninfected CD34 procontrol hemopoiesis [12] . It has been reported that cell types in both stromal and hemopoietic cell compartments are suscepgenitor cells. We also determined whether any effects could be countered by use of antiretroviral agents, namely zidovudine tible to infection with HIV in vitro and in vivo.
Previous studies from this and other laboratories have demor didanosine. Confluent irradiated stroma infected with HIV Ba-L was recharged with CD34 cells with and without zidovudine onstrated macrophages to be the major target cell for HIV infection in bone marrow stroma [13, 14] . There remains much or didanosine. The clonogenic capacity of the progenitor cells and their apoptotic state were assessed weekly by use of semicontroversy surrounding the possible infection of progenitor solid methylcellulose cultures and flow cytometry, respectively.
Poole, UK), 10% horse serum (Sigma), 100 IU/mL penicillinmL interleukin-3 (4.9 1 10 6 U/mg; Novartis Pharmaceuticals). Cell-medium suspension (1 mL) was plated into each of two petri streptomycin (Sigma), 100 IU/mL glutamine (Life Technologies), and 10 06 M hydrocortisone sodium succinate (Sigma), at a concendishes and incubated at 37ЊC in humidified air with 5% CO 2 . After 14 days of incubation, the following colony types were scored: tration of 10 7 cells/flask in a volume of 10 mL. The flasks were incubated at 37ЊC in humidified air with 5% CO 2 . Cultures were granulocyte-macrophage colony-forming units (CFU-GM), erythroid burst-forming units (BFU-E), and mixed colonies (CFUfed weekly by demi-depopulation of the nonadherent cells and replacement with supplemented IMDM. Cultures were maintained GEM).
7-amino actinomycin D (7AAD) staining.
Remaining nonadfor Ç4 weeks until stroma reached confluence.
Elimination of progenitor cells. At confluence, LTBMC were herent cells taken from LTBMC each week were stained with 7AAD, a fluorescent DNA-binding dye that defines live, apoptotic, x-ray-irradiated with a single dose of 1000 rad to eliminate surviving progenitor cells. This was shown to have no effect on HIV and dead populations by flow cytometry [20] . Nonadherent cells (õ1 1 10 6 ) were washed twice in PBS supplemented with 1% infection of LTBMC (data not shown).
Infection of stroma. LTBMC were infected with HIV-1 Ba-L FCS and 0.05% Na azide, resuspended in 900 mL of PBS and 100 mL of 7AAD (200 mg/mL; Calbiochem-Novabiochem, Notting-(Medical Research Council-AIDS-Directed Programme, South Mimms, UK) using a modification of a method previously deham, UK), and incubated for 20 min at 4ЊC, protected from light. After centrifugation, the supernatant was removed and the cells scribed [14] . Briefly, 1.5 mL of cell-free virus stock supernatant, or mock supernatant, was added to each flask and incubated for 2 were fixed in 500 mL of paraformaldehyde (2%). Unstained fixed cells were used as controls. h, fresh IMDM was added, and the cultures were incubated overnight at 37ЊC. The stroma was then washed three times with PBS, Samples were analyzed by FACScan (Becton Dickinson) within 30 min of fixing to avoid leaching of 7AAD. Data on Ç50,000 fresh supplemented medium was added, and the cultures were maintained for Ç10-14 days.
cells were acquired and analyzed by creating a scattergram of forward light scatter versus 7AAD fluorescence. Regions were Staining and purification of CD34 progenitor cells. BMMC were stained for CD34 by incubating with the following: human drawn around populations having negative, dim, and bright 7AAD fluorescence, defining live, apoptotic, and dead cell populations, gamma globulins (30 mg/10 6 BMMC; Sigma) for 10 min at 4ЊC; anti-CD34 antibody (10 mL/10 6 BMMC; QBEND10; Immunotech, respectively, and the proportion of cells within each region was calculated [20] . Marseilles, France) for 30 min at 4ЊC, followed by two washes in PBS with 1% FCS; and goat anti-mouse IgG conjugated to HIV-1 p24 core antigen analysis. Supernatants were collected between days 10 and 14 and assayed for HIV replication before phycoerythrin (6 mL/10 6 BMMC; DAKO, High Wycombe, UK) for 30 min at 4ЊC, followed by two washes in PBS with 1% FCS.
recharge of CD34 cells by p24 ELISA (DuPont NEN, Stevenage, UK), as stipulated by the manufacturer. The cells were then resuspended in PBS at 10 6 /mL and kept at 4ЊC. A negative control was set up concomitantly by use of a Nucleoside analogue titrations. To assess the toxicity of zidovudine and didanosine, a series of committed progenitor assays was nonspecific mouse IgG 1 .
CD34 cells were purified with a cell sorter (FACStar Plus; Becset up incorporating zidovudine or didanosine at concentrations ranging from 10 04 M to 10 09 M. ton Dickinson, Oxford, UK). The whole nucleated cell population (excluding red cells and cell debris) was analyzed by use of a Statistical analysis. Statistical significance of data was assessed by application of paired t tests of log-transformed data and scattergram of right-angle light scatter against fluorescence. Regions were drawn defining a population with low right-angle scatmultiple comparisons correction. ter and high fluorescence. This population was then sorted in enrich mode at 5000-6000 cells/s and subsequently in normal-R mode at 200-500 cells/s. Cells were collected into IMDM supplemented Results with 10% FCS. The frequency of CD34 cells was assessed both before and after sorting, and the purity of the sorted population recharging with purified CD34 cells. We have previously deterCommitted bone marrow progenitor assay. Recharged mined that maximal HIV replication is reached 10 -14 days LTBMC were fed by demi-depopulation weekly, and fresh meafter infection; productive HIV infection of LTBMC in this dium containing either zidovudine or didanosine was added. The study was confirmed by p24 ELISA (data not shown) [14] . Addition of zidovudine to control cultures suppressed CFU-GM, although its effects were less profound than those of HIV infection. Addition of zidovudine to HIV-infected LTBMC had no effect on the reduced CFU-GM numbers observed in nontreated HIV-infected LTBMC ( figure 4A ). Addition of didanosine had no effect on CFU-GM numbers produced from nonadherent cells from either control or HIV-infected cultures ( figure  4B ). Committed bone marrow progenitor assays for BFU-E and mixed colonies (CFU-GEM) were also done on control and HIV-infected LTBMC. Production of these erythroid colonies from control cultures was very short-lived and was not present by week 2 of culture. Although HIV infection of LTBMC appeared to impair the ability of nonadherent cells to produce erythroid colonies, data were not statistically significant be- To assess effects of antinucleoside analogues in current therapeutic use on production of nonadherent cells by HIV-infected and control LTBMC, cultures were recharged with purified CD34 cells in the presence of zidovudine or didanosine. Addition of zidovudine to control LTBMC produced a suppression of total nonadherent cell numbers similar to that seen in HIVinfected cultures ( figure 2A) . The greatest suppression of nonadherent cell numbers was observed in HIV-infected LTBMC cultures treated with zidovudine, although this was not statistically significant, suggesting a possible synergistic reduction in production of nonadherent cells. In contrast, didanosine, when added to control cultures, did not produce suppression of nonadherent cell counts (figure 2B). Furthermore, addition of didanosine had no effect on the reduction in nonadherent cell counts observed in HIV-infected LTBMC.
Effects of HIV infection on production of nonadherent cells
To determine the cytotoxicity of zidovudine and didanosine, short-term clonogenic assays were carried out (table 1) . These data demonstrated that zidovudine was cytotoxic at therapeutic levels, while didanosine showed little cytotoxicity at levels far higher than in vivo therapeutic tissue levels.
Effects of HIV infection of LTBMC on production of committed bone marrow progenitor cells.
Experiments were done to determine the effects of HIV infection of LTBMC on production of committed granulocyte-macrophage progenitor cells. Nonadherent cells harvested from control and HIV-infected LTBMC, recharged with CD34 cells, were assessed for their ability to form CFU-GM. Nonadherent cells from control LTBMC produced 2 -4 x 10 3 CFU-GM/week over 4 weeks of culture. HIV infection of LTBMC resulted in significant reduction in CFU-GM numbers (P õ .05 -.01) between weeks 
Effects of HIV infection of LTBMC on progenitor cell viability.
Release of HIV and HIV proteins (gp120, Tat, Nef) from HIV-infected bone marrow stroma may have direct cytotoxic effects on progenitor cells, leading to apoptosis and cell death [4 -6] . Thus, effects of HIV infection of LTBMC on apoptosis and cell death in nonadherent populations of LTBMC recharged with CD34 cells were investigated. Nonadherent cells were harvested from control and HIV-infected LTBMC and analyzed for levels of apoptosis and cell death by flow cytometry after staining with 7AAD [20] . HIV infection of LTBMC was demonstrated to have no effect on the proportion of apoptotic or dead nonadherent cells compared with nonadherent cells from control LTBMC (P Å not significant) (figure 5).
Addition of zidovudine to control or HIV-infected LTBMC increased percentages of apoptotic and dead nonadherent cells by 30% -35% (figure 6A) in nonadherent cells from both con- To determine whether suppression of LTBMC function observed in this study could be reversed by current nucleoside analogues in therapeutic use, experiments were done in the presence of zidovudine or didanosine. Zidovudine alone was shown to suppress production of both nonadherent and committed progenitor cells in control noninfected LTBMC. Zidovudine also produced a possible synergistic suppression of nonadherent cells from HIV-infected LTBMC. In contrast, didanosine had no suppressive effects on production of nonadherent and committed progenitor cells from control noninfected LTBMC and did not reverse suppressed production of nonadherent cells from HIV-infected LTBMC. In this study, we are only comparing the difference in suppression between HIV-infected and trol and HIV-infected LTBMC. In contrast, addition of didanosine to either control or HIV-infected LTBMC had no effect on percentage of apoptotic and dead cells in nonadherent populations (figure 6B).
Discussion
This study demonstrates that HIV infection of LTBMC leads to suppression of normal bone marrow function. This was demonstrated by a decrease in production of nonadherent and committed progenitor cells from HIV-infected LTBMC recharged with noninfected CD34 progenitor cells. Previous studies have investigated the effects of HIV infection on LTBMC function. Continual exposure of LTBMC to T cell -tropic strains of HIV has been demonstrated to impair production of nonadherent cells and CFU-GM without significant infection of bone marrow macrophages or progenitor cells [21] . Schwartz et al. [22] demonstrated that infection of LTBMC with macrophage-tropic isolate HIV-1 ADA , producing endogenous virus within such cultures, reduced CFU-GM. In addition, HIV-2 infection of LTBMC has been demonstrated to impair CFU-GM and BFU-E production, dependent on the virus inoculum [5, 23] . Data reported in this study confirm and extend these previous reports.
In contrast, Marandin et al. [24] observed no suppression of CFU-GM or BFU-E production with HIV-1 Ba-L isolate used in with 10 -14 days in this study.
/ 9d3b$$de20 10-23-97 13:45:30 jinfa UC: J Infect noninfected cultures and make no interpretation as to the degree observations and strongly suggests that the observed suppressive effects of zidovudine on hemopoiesis are mediated of suppression between HIV-infected conditions, such as in the presence or absence of zidovudine or didanosine.
through induction of apoptosis and cell death in progenitor cells. The mechanism of action is different from that observed Inability of didanosine (used at concentrations known to block HIV infection [data not shown]) to reverse suppressed for HIV infection of LTBMC. Such data suggest that in HIVinfected patients, HIV infection of bone marrow stroma and production of nonadherent and committed progenitor cells from HIV-infected LTBMC demonstrated that such suppression was zidovudine therapy may act synergistically, through different mechanisms, to impair hemopoiesis. This would suggest that not mediated by productive infection of progenitor cells. However, this does not rule out the possibility that suppressive zidovudine treatment should be precluded in patients demonstrating hematologic abnormalities, while didanosine would effects might occur during interaction of HIV with its receptor or coreceptor or during virus-cell fusion. In addition, such data need no such preclusion.
In conclusion, this study demonstrates that HIV infection of should be interpreted only within time constraints of the described experiments and do not exclude the possibility that LTBMC induces profound suppression of bone marrow function, resulting in reduced production of nonadherent and com-HIV infection of such cells might impair their longer-term viability or function. However, these data demonstrate that mitted progenitor cells. Such effects may account for hematologic abnormalities seen in HIV-infected patients and, on the failure of bone marrow function is mediated via direct HIV infection of bone marrow stroma alone. We and others have in vitro evidence presented in this study, these would be compounded by zidovudine therapy. previously demonstrated that bone marrow stromal macrophages are the principal target cells of infection in LTBMC [14, 22, 25] . Thus, suppression of bone marrow function is likely to be mediated either by release of HIV proteins, with
